Back to Directory

Tirzepatide + Cagrilintide (CagriSema equivalent)

Metabolic & Weight Management

Investigational combination of GIP/GLP-1 agonist with amylin analog for maximum weight loss.

Key Benefits

  • ✓Maximum weight loss potential
  • ✓Dual mechanism
  • ✓Enhanced satiety
  • ✓Combines incretin and amylin pathways

Dosing Information

Dosage Range
Under development
Frequency
Weekly anticipated
Typical Duration
Clinical development

Detailed Protocol

Research and development stage. Various combination approaches being studied. Weekly administration expected.

About Tirzepatide + Cagrilintide (CagriSema equivalent)

Combination therapy approach (similar to Novo Nordisk CagriSema program). While CagriSema is semaglutide + cagrilintide, this concept represents combining incretin agonists with amylin analogs for synergistic weight loss.

Research Notes

Combination therapy approach showing promise in trials. CagriSema trials show 25%+ weight loss. Combination strategies likely future of obesity treatment.

Get Peptide Research Updates

Newsletter signup

Please wait...

Thanks for signing up! You will receive an email to confirm your subscription.

Potential Side Effects

  • •Expected combination of GI effects
  • •Investigational

Always consult with a healthcare professional before starting any peptide therapy.